



Therapeutic Monoclonal Antibodies Markets

Published: 2009-JUN-01

Pages: 112

Format: PDF

Description

Antibodies are proteins in the immune system that help the body defend against foreign invasion, particularly from pathogens and toxins. As such, a human-engineered therapeutic monoclonal antibody (mAb) is protein derived from the immune system through recombinant DNA technology that has the ability to combine specifically with a target protein that plays a role in a disease process. With this unique ability to specifically target diseased cells while leaving healthy cells unaffected, monoclonal antibodies can serve to diagnose and treat a wide range of medical conditions. Areas such as breast cancer therapy have benefited greatly since the advent of drugs like Herceptin (trastuzumab) that interferes with the HER2/neu receptor. Indeed, the field of therapeutic monoclonal antibodies potentially has far-reaching and paradigm-shifting implications for biology, drug discovery, and medical treatment of disease. The discipline has already yielded discoveries that have been used for drug delivery and diagnostic purposes, and other exciting new therapeutic applications. This TriMark Publications report reviews the market for medical products based on emerging therapeutic monoclonal antibodies. It defines the dollar volume of sales in the U.S. and worldwide, and it analyzes the factors that influence the size and the growth of the market segments. The study goes on to discuss in detail the trends that have developed which have stimulated this market and surveys many of the companies marketing, manufacturing or developing monoclonal antibodies therapies. Monoclonal antibodies for non-therapeutic purposes--used primarily in life science and research applications--are not discussed in this review. Moreover, antibody process technology is not covered. Special effort was made to include mention of smaller companies that are or potentially could have an impact on their industry far in excess of their current size. Each company is discussed in depth with a section on the history of the company, the product line, business and marketing analysis, and a subjective commentary of the position of the company in its market.

Table of Contents

1. Introduction	5
1.1 Statement of Report	5
1.2 Objectives of this Report	5
1.3 Scope of the Report	6
1.4 Methodology	7
1.5 Executive Summary	8
2. The State of Therapeutic Monoclonal Antibody Technology	10
2.1 State of the Pharmaceutical Industry	10
2.2 Antibodies as an Alternative Pharmaceutical Agent	16
2.3 Current Status of Antibody Therapeutics	19
2.4 Demands of Antibody Therapeutics Development	23
3. Recent Technology Trends	24
3.1 Classic Design of Antibodies	24
3.1.1 Chimeric Monoclonal Antibodies	25
3.1.2 Humanized Monoclonal Antibodies	25
3.1.3 Totally Human Antibodies	26
3.1.4 Monoclonal Antibody Processing	26
3.2 Monoclonal Antibodies Therapeutics	26
3.2.1 Naked Monoclonal Antibodies	26
3.2.2 Conjugated Monoclonal Antibodies	27
3.3 Synthetic Antibodies, Unique Scaffolds	28
3.4 Screening and Selection of Antibodies	28
3.5 Novel Antibody Modifications: Glycosylation, Pegylation, Polymer Conjugations	29
3.5.1 Miniaturizing and Delivering Antibody Drugs	30
3.5.2 Recombinant Polyclonals	30
3.6 Monoclonal Antibody Purification	31
4. Industry Challenges	32

4.1 Introduction: Challenges Affecting the U.S. Therapeutic Monoclonal Antibodies Market	32
4.2 Increasing Costs and Complexities of Clinical Trials	33
4.3 Long-term Safety and Efficacy	33
4.3.1 Post-marketing Surveillance of Monoclonal Antibodies	34
4.4 High Cost of Monoclonal Antibodies	34
4.5 Restricted Government Healthcare Spending	35
4.6 Intellectual Property Thicket	35
4.7 Government Regulation	36
4.8 Third-party Reimbursement Environment	37
5. Pipeline Analysis	38
5.1 Overview of the Monoclonal Antibodies Pipeline	38
5.1.1 Anti-Cancer Antibodies	41
5.1.2 Profiles of Important Monoclonal Antibodies in Oncology	41
5.1.2.1 Avastin	42
5.1.2.2 Phase I Trials of Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy	44
5.1.2.3 Adecatumumab (MT201) in Combination with Chemotherapy	45
5.1.2.4 Herceptin	45
5.1.2.5 Pertuzumab, a HER2 Dimerization Inhibitor	46
5.1.2.6 Cetuximab	47
5.1.2.7 Prostate Cancer: Will Vaccines Lead the Way?	47
5.1.2.8 Recent Trial of an Anti-prostate Cancer Monoclonal Antibody	47
5.1.2.9 Anti-melanoma Antibodies	48
5.1.2.10 Other Anti-cancer Monoclonal Antibodies	48
5.1.3 Monoclonal Antibodies in Autoimmune and Inflammatory Disorders	48
5.1.3.1 Type 1 Diabetes	49
5.1.3.2 Rheumatoid Arthritis	49
5.1.4 Monoclonal Antibodies in Organ Transplants	50
5.1.5 Monoclonal Antibodies in Cardiovascular Disorders	50
5.1.5.1 Ablynx	50
5.1.5.2 ThromboGenics/BioInvent International	50
5.1.5.3 Pexelizumab: A Recombinant Humanized Single Chain Monoclonal Antibody	51
5.1.6 Monoclonal Antibodies in Infectious Diseases	51
5.1.7 Monoclonal Antibodies in Miscellaneous Indications	51
5.1.7.1 Alzheimer's Disease	51
5.1.7.2 Parkinson's Antibody Therapy	52
5.2 U.S. Therapeutic Monoclonal Antibodies Market	52
5.2.1 Market Dimensions	52
6. Short-term Market Predictions	54
6.1 Total Revenue Forecasts	54
6.2 Segment Revenue Forecast	55
6.2.1 Oncology, Arthritis, Immune and Inflammatory Disorders (AIID)	55
6.3 Competitive Analysis Forecast	56
6.3.1 Competition between Similar Products	57
6.3.2 Competitive Factors	58
6.4 Conclusions	58
6.4.1 A Rocky Road	58
6.4.2 The Only Solution to High Medical Costs is Research	59
7. Antibody Technology Companies: Profiles	61
7.1 Abbott Laboratories	61
7.2 Abgenix	62
7.3 Ablynx	62
7.4 Aeres	62
7.5 Affimed Therapeutics AG	63
7.6 Affitech AS	63
7.7 Agensys	63
7.8 Alexion Pharmaceuticals	63
7.9 Amgen	64
7.10 Antisoma	65
7.11 ApoLife, Inc.	65
7.12 Applied Molecular Evolution, Inc.	66
7.13 Arana Therapeutics	66
7.14 Astellas Pharma	66
7.15 AstraZeneca plc	67
7.16 Biogen Idec, Inc.	68
7.17 BioInvent International AB	69
7.18 Biosite Discovery	70
7.19 Biovation Ltd.	70
7.20 BioWa	70
7.21 Boehringer Ingelheim	71
7.22 Cambridge Antibody Technology Group	71
7.23 Crucell NV	71
7.24 Cytogen	72
7.25 Dyax	72
7.26 Eisai Co., Ltd.	73

7.27 Elan Corporation	73
7.28 Eli Lilly	74
7.29 Elusys Therapeutics	75
7.30 Enzon Pharmaceuticals	75
7.31 Genentech	76
7.32 Genmab A/S	82
7.33 Genovac GmbH	83
7.34 Genzyme Corporation	83
7.35 GlaxoSmithKline plc	84
7.36 ImClone Systems	85
7.37 ImmunoGen	86
7.38 Immunomedics	87
7.39 InNexus Biotechnology, Inc.	89
7.40 Johnson & Johnson	89
7.41 Medarex	91
7.42 MedImmune	92
7.43 Merus BV	92
7.44 Micromet	93
7.45 Millegen	93
7.46 Millennium Pharmaceuticals	94
7.47 MorphoSys AG	94
7.48 Novartis	94
7.49 Peregrine Pharmaceuticals, Inc.	95
7.50 PDL BioPharma	96
7.51 Philogen	97
7.52 Philotec	98
7.53 Phylos	98
7.54 Roche	98
7.55 Sanofi-Aventis	99
7.56 Scil Proteins	101
7.57 Seattle Genetics	101
7.58 Symphogen A/S	103
7.59 Tanox	103
7.60 ThromboGenics NV	103
7.61 Trion Pharma	103
7.62 Viventia Biotech, Inc.	104
7.63 Wyeth	104
7.64 Xcellerex	105
7.65 Xencor, Inc.	105
7.66 Xoma Ltd.	105

References	108
------------	-----

INDEX OF FIGURES

Figure 2.1: Worldwide Pharmaceutical Sales and R&D Expenditures, 2000-2013	11
Figure 2.2: International Per Capita Healthcare Spending by Country	13
Figure 2.3: Total Spending on Healthcare in the U.S., 1960-2007	15
Figure 2.4: Percentage Breakdown of U.S. Healthcare Spending, 2008	15
Figure 3.1: Basic Structure of the Antibody Molecule	25
Figure 5.1: Global Market for Protein Therapeutics, 2007-2013	53
Figure 6.1: Sales of the Five Leading Antibodies, 2008	56

INDEX OF TABLES

Table 2.1: Number of New Drug Applications to the FDA, 2000-2008	11
Table 2.2: New Drug Approvals from FDA, 2000-2008	12
Table 2.3: Percentage of GDP Healthcare Spending by Country, 2008	13
Table 2.4: Life Expectancy Rate by Country, 2008	14
Table 2.5: Development Time for Major Drugs for Top U.S. Pharmaceutical Companies	16
Table 2.6: Number of FDA "Black-box" Warnings, 2003-2007	20
Table 2.7: Collaboration and Mergers	21
Table 2.8: Worldwide Spending of Specialty Pharmaceuticals, 2003-2010	22
Table 2.9: New Drug Development from Existing Drugs	22
Table 3.1: Timeline of Immunological Discoveries	24
Table 3.2: Antibody Screening and Selection Technologies	29
Table 3.3: FDA-Approved Rapid HIV Antibody Screening Tests	29
Table 4.1: Currently Approved Therapeutic Antibodies	32
Table 5.1: Therapeutic Antibodies in the Development Pipeline	38
Table 5.2: Currently Approved Anti-Cancer Antibodies	41
Table 5.3: Status of Clinical Studies Involving Avastin	43
Table 5.4: Market for Avastin Therapeutic Antibodies, 2006-2012	43
Table 5.5: Rise in Herceptin Sales, 1998-2008	45
Table 5.6: Monoclonal Antibodies in Clinical Trials for Cardiovascular Diseases	50
Table 6.1: Projected World Market for Therapeutic Monoclonal Antibodies, 2008-2012	54

Table 6.2: Market Record and Outlook for Oncological Therapeutic Antibodies, 2006-2012 55

Table 6.3: Recorded and Anticipated Sales Growth for Anti-inflammatory Monoclonal Antibodies, 2006-2012 55

Table 7.1: Genentech's Operating Revenue, 2004-2008 76

Table 7.2: Genentech's Product Sales, 2006-2008 77

Table 7.3: Genentech's Product Licensee Products 79

Table 7.4: Genentech's Products in Development 79

Ordering

Order Online - <http://www.bioseeker.com/market-research-report/therapeutic-monoclonal-antibodies-markets.html>

Order by Fax - using the form below

Order by Post - print the order form below and send to:

BioSeeker Group
Björnnäsvägen 21
11419 STOCKHOLM
SWEDEN

Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to +46-8-56849191. If you have any questions please visit <http://www.bioseeker.com/market-research-report/contacts/>

Order Information

Please verify that the product information is correct:

Product Name: **Therapeutic Monoclonal Antibodies Markets**

Web Address: <http://www.bioseeker.com/market-research-report/therapeutic-monoclonal-antibodies-markets.html>

Format: PDF

Price: 1699 EUR (Single User License)

Delivery of hard copy or CD-ROM is subject to a Courier charge of 50 EUR.

Delivery within Sweden is subject to VAT at 25%.

Contact Information

Please enter all the information below in **BLOCK CAPITALS**

Title: _____

Name: _____

Email Address:* _____

Job Title: _____

Organization: _____

EU companies must supply: VAT / BTW / MOMS

MWST / IVA / FPA number: _____

Address: _____

Zip Code: _____

City: _____

State: _____

Country: _____

Phone Number: _____

Fax Number: _____

Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by credit card:

American Express

Master Card

Visa

Cardholder Name: _____

Expiry Date (MM/YY): _____

Card Number: _____

CVV Number: _____

Pay by check:

Please post the check, accompanied by this form, to:

BioMarket Group

Björnnäsvägen 21

11419 STOCKHOLM

SWEDEN

Pay by wire transfer: Please transfer funds to:

Account number: 43521169

Swift code: HANDSESS

IBAN number: SE74 6000 0000 0000 4352 1169

Bank Address: Handelsbanken, Stockholm, Sweden

If you have a Marketing Code please enter it below:

Marketing Code: _____

Please supply purchase order number if needed: _____

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, Gmail)

Please note that by ordering from BioSeeker Group you are agreeing to our Terms and Conditions at

<http://www.bioseeker.com/market-research-report/biomarket-group-full-terms-and-conditions/>

Please fax this form to: +46-8-56849191